Immuno Cure secured HK$8 million in funding from HKSTP to conduct a phase 1 clinical trial of ICVAX, a therapeutic HIV vaccine. ICVAX was developed using Immuno Cure's patented PD-1-Enhanced DNA vaccine platform and aims to induce viral-specific T cells to achieve functional cure of HIV. The clinical trial will evaluate the safety and immunogenicity of ICVAX in stable HIV patients in China and take 18-24 months to complete. Immuno Cure previously received HK$8.4 million from the ITF and is collaborating with HKU AIDS Institute, who received HK$47 million for HIV research.